Generic Talconex now available
Sandoz this week introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.
Sandoz recently introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.
Talconex is a vitamin D analogue and corticosteroid combination product used to treat adults with psoriasis vulgaris, which affects approximately 2% of the U.S. population.
“Sandoz is proud to be first-to-market with a generic version of this important therapy,” said Peter Goldschmidt, president of Sandoz US. “This launch further broadens our strong offering of differentiated generic dermatology products.”
Tolmar Inc. owns the Abbreviated New Drug Application for the product and received FDA approval for a generic version. Sandoz will market its calcipotriene and betamethasone dipropionate ointment in partnership with Tolmar.
Talconex produced $96 million in U.S. sales in 2013, according to IMS Health. Sandoz’s generic version will be available in 60-g and 100-g tubes.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
